Crossbow

Crossbow

Private
Cambridge, MassachusettsHealthcare & Life Scienceswww.crossbowtx.com

Last Round

Series B

Mar 18, 2026

Est. Valuation

$112.55M

Total Funding Raised

$157M

Company Overview

Crossbow Therapeutics is a biotechnology company focused on developing next-generation immunotherapies that precisely target previously unreachable cancer cell proteins, significantly enhancing treatment options for cancer patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

T-Bolt platformTCR-mimetic antibodiesT-cell engagerscancer therapeuticsbispecific antibodiesimmuno-oncologyintracellular antigensundruggable targetsantibody discoverydrug discovery platformacute myeloid leukemiaAMLsolid tumor therapymyelodysplastic syndromesMDSpreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Crossbow Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Crossbow Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMar 18, 2026
Series AJul 11, 2023

Key People

Founding team and executive leadership

Briggs Morrison

Chief Executive Officer

Executive Team

Crossbow Investors

Notable investors and investment history

InvestorRounds
Libbs VenturesSeries B
LifeLink VenturesSeries B
Sixty Degree CapitalSeries B
Taiho VenturesSeries B
MPM BioImpactSeries B, Series A, Seed
Arkin Bio CapitalSeries B
BVF Partners L.P.Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    $77M round completed.

  • Mar 18, 2026

    Developing novel T-cell engager therapies targeting cancer cells.

Crossbow Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Crossbow Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Crossbow's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range40
Year Founded2021
Last FundingMar 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.